Vera Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
FDA granted accelerated approval to TRUTAKNA for adults with IgA nephropathy, based on robust Phase III data showing significant proteinuria reduction and a favorable safety profile. The product will be available within weeks, with a trained sales force and broad payer support.
-
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were raised, and quorum was confirmed. Final voting results will be filed on Form 8-K.
-
Atacicept is on track for FDA approval in July, with strong clinical data and a broad label anticipated. Commercial launch preparations are advanced, targeting a large, young, commercially insured U.S. population, and leveraging a patient-friendly auto-injector. Ongoing studies and a robust IP portfolio support future growth.
-
Atacicept is on track for a July 2026 commercial launch in IgAN, supported by strong phase III efficacy and safety data, robust financials, and a dedicated commercial team. Ongoing trials and new formulations aim to expand its reach, with updated guidelines and additional data expected this year.
Fiscal Year 2025
-
Atakicept's positive Phase III results in IgAN nephropathy highlight strong efficacy and a placebo-like safety profile, with regulatory review underway and a commercial launch planned for next year. The therapy's dual BAF-APRL inhibition offers a novel approach, and pipeline expansion targets broader renal and autoimmune indications.
-
Phase 3 data for atacicept in IgA nephropathy showed strong efficacy and safety, supporting a planned U.S. launch in 2026. The pipeline is expanding into broader kidney and autoimmune indications, with monthly and long-interval dosing in development.
-
Recent clinical data show atacicept achieved significant reductions in proteinuria and hematuria, with GFR stability over two years and a favorable safety profile. Regulatory filings are underway, and broader studies in autoimmune kidney diseases are ongoing, with more data expected into 2026.
-
Atacicept's Phase III interim results show strong efficacy and safety in IgA nephropathy, with significant reductions in proteinuria and favorable biomarker outcomes across all patient subgroups. The product is highly anticipated by nephrologists, and the company is financially prepared for a 2026 launch and further pipeline expansion.
-
Atacicept has demonstrated robust, consistent efficacy in IgA nephropathy, with a BLA filing planned for Q4 and anticipated market entry by mid-next year. Commercial preparations are advanced, the auto-injector is well received, and the pipeline is expanding into broader kidney and autoimmune indications.
-
Atacicept showed strong phase III efficacy and safety in IgAN, with at-home dosing and robust GFR data supporting its use as a foundational therapy. Regulatory filing is planned for Q4, with commercial launch targeted for mid-2026 and significant market opportunity anticipated.
-
The ORIGIN phase III trial of atacicept in IgA nephropathy met its primary endpoint, showing a 46% reduction in proteinuria at week 36 and a favorable safety profile, supporting plans for a BLA submission in Q4. Atacicept’s differentiated mechanism and at-home administration position it strongly for commercial success.
-
Phase III data for atacicept in IgA nephropathy is expected in Q2, supporting a BLA filing in the second half of the year. Commercial and regulatory strategies are well advanced, with pipeline expansion targeting broader renal and autoimmune indications.
-
Atacicept, a dual BAFF/APRIL modulator, is advancing in phase III for IgAN with strong two-year efficacy and safety data, aiming for a 2026 launch. Pipeline expansion includes new indications, monthly dosing, and a next-gen molecule, VT109, supported by robust financials.
Fiscal Year 2024
-
Phase 2 data showed atacicept stabilized kidney function in IgA nephropathy, with phase 3 results expected in Q2 2025 to support a BLA filing. Commercial launch is targeted for 2026, with ongoing studies for broader indications and monthly dosing.
-
Atacicept has set a new standard in IgA nephropathy by demonstrating stable GFR over two years and high safety, with phase III data expected in Q2 next year. Expansion into broader and adjacent autoimmune kidney diseases could increase the addressable U.S. population to nearly 250,000 patients.
-
The ORIGIN Phase IIb study of atacicept in IgA nephropathy showed sustained reductions in pathogenic IgA, proteinuria, and hematuria, with near-normal stabilization of kidney function over 96 weeks and a strong safety profile. At-home, weekly administration was highly acceptable, and phase III results are expected in 2025.
-
Atacicept is advancing as a potential best-in-class therapy for IgAN and other autoimmune kidney diseases, with pivotal phase 3 data expected in 2025 and a U.S. launch targeted for 2026. The clinical program is expanding to cover up to 230,000 patients, supported by strong financials and a robust IP strategy.
-
Atacicept, a dual BAFF/APRIL inhibitor, demonstrated strong efficacy in IgA nephropathy, with significant reductions in immune complexes, proteinuria, and hematuria, and stable GFR over 72 weeks. Two-year data and a commercial launch are anticipated in 2026.